Rapamycin Inhibits Activation of AMPK-mTOR Signaling Pathway-Induced Alzheimer’s Disease Lesion in Hippocampus of Rats with Type 2 Diabetes Mellitus

Qin Sun,Ling-Ling Wei,Min Zhang,Ting-Xin Li,Chun Yang,Shao-Ping Deng,Qing-Cui Zeng
DOI: https://doi.org/10.1080/00207454.2018.1491571
2018-01-01
International Journal of Neuroscience
Abstract:BACKGROUND:Type 2 diabetes mellitus (T2DM) is strongly correlated with Alzheimer's disease (AD). Rapamycin has important uses in oncology, cardiology and transplantation medicine. This study aims to investigate effects of rapamycin on AD in hippocampus of T2DM rat by AMPK/mTOR signaling pathway.METHODS:Morris water maze test was applied to evaluate the learning and memory abilities. The fasting plasma glucose (FBG), glycosylated haemoglobin, total cholesterol, triglyceride and serum insulin level were measured. RT-qPCR and Western blot analysis were performed to test expression of AMPK and mTOR. Immunohistochemistry was used to detect the Aβ deposition and immunoblotting to test the total tau, p-tau and Aβ precursor APP expressions.RESULTS:After treated with rapamycin, T2DM rats and rats with T2DM and AD showed increased learning-memory ability, and decreased levels of FBG, glycosylated hemoglobin, total cholesterol, triglyceride and serum insulin, decreased expression of APP and p-tau, increased AMPK mRNA expression and p-AMPK and decreased Aβ deposition, mTOR mRNA expression and p-mTOR.CONCLUSION:The study demonstrated that rapamycin reduces the risk of AD in T2DM rats and inhibits activation of AMPK-mTOR signaling pathway, thereby improving AD lesion in hippocampus of T2DM rats.
What problem does this paper attempt to address?